241 related articles for article (PubMed ID: 24096176)
21. Germline genetic variants in men with prostate cancer and one or more additional cancers.
Pilié PG; Johnson AM; Hanson KL; Dayno ME; Kapron AL; Stoffel EM; Cooney KA
Cancer; 2017 Oct; 123(20):3925-3932. PubMed ID: 28657667
[TBL] [Abstract][Full Text] [Related]
22. High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
Bogdanova NV; Antonenkova NN; Rogov YI; Karstens JH; Hillemanns P; Dörk T
Clin Genet; 2010 Oct; 78(4):364-72. PubMed ID: 20569256
[TBL] [Abstract][Full Text] [Related]
23. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
Gayther SA; de Foy KA; Harrington P; Pharoah P; Dunsmuir WD; Edwards SM; Gillett C; Ardern-Jones A; Dearnaley DP; Easton DF; Ford D; Shearer RJ; Kirby RS; Dowe AL; Kelly J; Stratton MR; Ponder BA; Barnes D; Eeles RA
Cancer Res; 2000 Aug; 60(16):4513-8. PubMed ID: 10969800
[TBL] [Abstract][Full Text] [Related]
24. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
[TBL] [Abstract][Full Text] [Related]
25. Prostate cancer progression and survival in BRCA2 mutation carriers.
Tryggvadóttir L; Vidarsdóttir L; Thorgeirsson T; Jonasson JG; Olafsdóttir EJ; Olafsdóttir GH; Rafnar T; Thorlacius S; Jonsson E; Eyfjord JE; Tulinius H
J Natl Cancer Inst; 2007 Jun; 99(12):929-35. PubMed ID: 17565157
[TBL] [Abstract][Full Text] [Related]
26. Effect of CHEK2 missense variant I157T on the risk of breast cancer in carriers of other CHEK2 or BRCA1 mutations.
Cybulski C; Górski B; Huzarski T; Byrski T; Gronwald J; Debniak T; Wokolorczyk D; Jakubowska A; Serrano-Fernández P; Dork T; Narod SA; Lubinski J
J Med Genet; 2009 Feb; 46(2):132-5. PubMed ID: 18930998
[TBL] [Abstract][Full Text] [Related]
27. Loss of heterozygosity at the BRCA2 locus detected by multiplex ligation-dependent probe amplification is common in prostate cancers from men with a germline BRCA2 mutation.
Willems AJ; Dawson SJ; Samaratunga H; De Luca A; Antill YC; Hopper JL; Thorne HJ;
Clin Cancer Res; 2008 May; 14(10):2953-61. PubMed ID: 18445692
[TBL] [Abstract][Full Text] [Related]
28. Mutation analysis of BRIP1/BACH1 in BRCA1/BRCA2 negative Chinese women with early onset breast cancer or affected relatives.
Cao AY; Huang J; Hu Z; Li WF; Ma ZL; Tang LL; Zhang B; Su FX; Zhou J; Di GH; Shen KW; Wu J; Lu JS; Luo JM; Yuan WT; Shen ZZ; Huang W; Shao ZM
Breast Cancer Res Treat; 2009 May; 115(1):51-5. PubMed ID: 18483852
[TBL] [Abstract][Full Text] [Related]
29. The frequency of the BLM*p.Q548X (c.1642C > T) mutation in breast cancer patients from Russia.
Imyanitov E; Prokofyeva D; Bogdanova N; Dörk T
Breast Cancer Res Treat; 2014 Dec; 148(3):695-6. PubMed ID: 25410042
[No Abstract] [Full Text] [Related]
30. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
[TBL] [Abstract][Full Text] [Related]
31. Skewed X chromosome inactivation and breast and ovarian cancer status: evidence for X-linked modifiers of BRCA1.
Lose F; Duffy DL; Kay GF; Kedda MA; Spurdle AB; ;
J Natl Cancer Inst; 2008 Nov; 100(21):1519-29. PubMed ID: 18957670
[TBL] [Abstract][Full Text] [Related]
32. The frequency of the BLM p.Q548X (c.1642C>T) mutation in breast cancer patients from Russia is no higher than in the general population.
Anisimenko MS; Kozyakov AE; Paul GA; Kovalenko SP
Breast Cancer Res Treat; 2014 Dec; 148(3):689-90. PubMed ID: 25399228
[No Abstract] [Full Text] [Related]
33. Role of HPC2/ELAC2 in hereditary prostate cancer.
Wang L; McDonnell SK; Elkins DA; Slager SL; Christensen E; Marks AF; Cunningham JM; Peterson BJ; Jacobsen SJ; Cerhan JR; Blute ML; Schaid DJ; Thibodeau SN
Cancer Res; 2001 Sep; 61(17):6494-9. PubMed ID: 11522646
[TBL] [Abstract][Full Text] [Related]
34. Phenocopy breast cancer rates in Israeli BRCA1 BRCA2 mutation carrier families: is the risk increased in non-carriers?
Bernholtz S; Laitman Y; Kaufman B; Shimon-Paluch S; Friedman E
Breast Cancer Res Treat; 2012 Apr; 132(2):669-73. PubMed ID: 22113258
[TBL] [Abstract][Full Text] [Related]
35. Coinheritance of BRCA1 and BRCA2 mutations with Fanconi anemia and Bloom syndrome mutations in Ashkenazi Jewish population: possible role in risk modification for cancer development.
Koren-Michowitz M; Friedman E; Gershoni-Baruch R; Brok-Simoni F; Patael Y; Rechavi G; Amariglio N
Am J Hematol; 2005 Mar; 78(3):203-6. PubMed ID: 15726604
[TBL] [Abstract][Full Text] [Related]
36. Genetic testing for hereditary prostate cancer: Current status and limitations.
Zhen JT; Syed J; Nguyen KA; Leapman MS; Agarwal N; Brierley K; Llor X; Hofstatter E; Shuch B
Cancer; 2018 Aug; 124(15):3105-3117. PubMed ID: 29669169
[TBL] [Abstract][Full Text] [Related]
37. Mutations in ATM, NBN and BRCA2 predispose to aggressive prostate cancer in Poland.
Wokołorczyk D; Kluźniak W; Huzarski T; Gronwald J; Szymiczek A; Rusak B; Stempa K; Gliniewicz K; Kashyap A; Morawska S; Dębniak T; Jakubowska A; Szwiec M; Domagała P; Lubiński J; Narod SA; Akbari MR; Cybulski C;
Int J Cancer; 2020 Nov; 147(10):2793-2800. PubMed ID: 32875559
[TBL] [Abstract][Full Text] [Related]
38. Risk of breast cancer in women with a CHEK2 mutation with and without a family history of breast cancer.
Cybulski C; Wokołorczyk D; Jakubowska A; Huzarski T; Byrski T; Gronwald J; Masojć B; Deebniak T; Górski B; Blecharz P; Narod SA; Lubiński J
J Clin Oncol; 2011 Oct; 29(28):3747-52. PubMed ID: 21876083
[TBL] [Abstract][Full Text] [Related]
39. Chromosomal instability associated with a novel BLM frameshift mutation (c.1980-1982delAA) in two unrelated Tunisian families with Bloom syndrome.
Ben Salah G; Salem IH; Masmoudi A; Ben Rhouma B; Turki H; Fakhfakh F; Ayadi H; Kamoun H
J Eur Acad Dermatol Venereol; 2014 Oct; 28(10):1318-23. PubMed ID: 24118499
[TBL] [Abstract][Full Text] [Related]
40. Excess breast cancer risk in first degree relatives of CHEK2∗1100delC positive familial breast cancer cases.
Adank MA; Verhoef S; Oldenburg RA; Schmidt MK; Hooning MJ; Martens JW; Broeks A; Rookus M; Waisfisz Q; Witte BI; Jonker MA; Meijers-Heijboer H
Eur J Cancer; 2013 May; 49(8):1993-9. PubMed ID: 23415889
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]